Maria R. Abbattista

23 Symonds St
Auckland, AUK 1010, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.

Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.

Journal: ACS medicinal chemistry letters

Published: July 24, 2023

Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 16, 2021

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 01, 2021

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.

Journal: Molecular cancer therapeutics

Published: May 05, 2021

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.

Journal: Molecules (Basel, Switzerland)

Published: September 20, 2020

Synthesis and antiproliferative activity of C- and N-terminal analogues of culicinin D.

Synthesis and antiproliferative activity of C- and N-terminal analogues of culicinin D.

Journal: Bioorganic & medicinal chemistry letters

Published: April 20, 2020

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications.

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications.

Journal: Theranostics

Published: April 08, 2020

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol.

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol.

Journal: Bioorganic & medicinal chemistry letters

Published: February 24, 2020

Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues.

Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues.

Journal: European journal of medicinal chemistry

Published: January 24, 2019

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

Journal: Biochemical pharmacology

Published: May 25, 2016

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Journal: Cancer biology & therapy

Published: April 15, 2015

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

Journal: Frontiers in oncology

Published: August 15, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026